CVE-2023-38955

CVE-2023-38955 is a high-severity vulnerability in Zkteco Bioaccess Ivs with a CVSS 3.x base score of 7.5. It is not currently listed as actively exploited by CISA, and its EPSS exploit-prediction score is low. The underlying weakness is classified as CWE-668.

Key facts

Description

ZKTeco BioAccess IVS v3.3.1 allows unauthenticated attackers to obtain sensitive information about all managed devices, including their IP addresses and device names.

Frequently asked questions

What is CVE-2023-38955?
ZKTeco BioAccess IVS v3.3.1 allows unauthenticated attackers to obtain sensitive information about all managed devices, including their IP addresses and device names.
How severe is CVE-2023-38955?
CVE-2023-38955 has a CVSS 3.x base score of 7.5, rated high severity. It is exploitable over network with low attack complexity, requires no privileges and no user interaction. Impact on confidentiality is high, integrity none, and availability none.
Is CVE-2023-38955 being actively exploited?
It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 1% (39th percentile), an estimate of the probability of exploitation in the next 30 days.
What products are affected by CVE-2023-38955?
CVE-2023-38955 affects Zkteco Bioaccess Ivs. See the affected-products list for the exact vulnerable versions.
How do I fix CVE-2023-38955?
Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround. Given its high severity, prioritise patching exposed systems.
When was CVE-2023-38955 published?
CVE-2023-38955 was published on 2023-08-03 and last updated on 2026-07-09.

References

Affected products (1)

More vulnerabilities in Zkteco Bioaccess Ivs

All CVEs affecting Zkteco Bioaccess Ivs →

Other CWE-668 (Exposure of Resource to Wrong Sphere) vulnerabilities

Browse all CWE-668 (Exposure of Resource to Wrong Sphere) vulnerabilities →